3,5-二氯-4-(3'-异丙基-4'-甲氧基苯氧基)-硝基苯 | 156740-82-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 3,5-二氯-4-(3'-异丙基-4'-甲氧基苯氧基)-硝基苯
• 英文名称: 1,3-dichloro-2-(3-isopropyl-4-methoxyphenoxy)-5-nitrobenzene
• 英文别名: 3,5-dichloro-4-(3'-isopropyl-4'-methoxyphenoxy)-nitrobenzene；4-(3-isopropyl-4-methoxy-phenoxy)-3,5-dichloro-nitrobenzene；3,5-dichloro-4-(4'-methoxy-3'-isopropyl-phenoxy)nitrobenzene；1,3-dichloro-2-(4-methoxy-3-propan-2-ylphenoxy)-5-nitrobenzene
• CAS: 156740-82-8
• 化学式: C₁₆H₁₅Cl₂NO₄
• 分子量: 356.205
• InChiKey: SMDQMOQILUMSOV-UHFFFAOYSA-N

物化性质

• 沸点：
  402.1±45.0 °C(Predicted)
• 密度：
  1.320±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  5.6
• 重原子数：
  23
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.25
• 拓扑面积：
  64.3
• 氢给体数：
  0
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  3,5-二氯-4-(3'-异丙基-4'-甲氧基苯氧基)-硝基苯 在 盐酸 、 tin(II) chloride dihydrate 作用下， 以 乙醇 、 水 为溶剂， 反应 3.0h， 以95%的产率得到3,5-dichloro-4-(3-isopropyl-4-methoxyphenoxy)aniline
  参考文献：
  名称：

  设计和合成新型3-羟基-环丁-3-烯-1,2-二酮衍生物，作为甲状腺激素受体β（TR-β）选择性配体。

  摘要：

  报道了新型3-羟基-环丁-3-烯-1,2-二酮衍生物的设计和合成，并在甲状腺荧光素酶受体测定中评估了它们的体外甲状腺激素受体选择性。3- [3,5-二氯-4-（4-羟基-3-异丙基苯氧基）-苯基氨基] -4-羟基-环丁-3-烯-1,2-二酮21对甲状腺激素受体β表现出选择性。

  DOI：

  10.1016/j.bmcl.2008.06.038
• 作为产物：
  描述：

  2-异丙基苯甲醚 在 双氧水 、 对甲苯磺酸 、 sodium hydrogensulfite 、 sodium hydroxide 、 三氯氧磷 作用下， 以 四氢呋喃 、 甲醇 、 正己烷 、 水 、 N,N-二甲基甲酰胺 为溶剂， 生成 3,5-二氯-4-(3'-异丙基-4'-甲氧基苯氧基)-硝基苯
  参考文献：
  名称：

  Rational Design of Potent and Selective Inhibitors of an Epoxide Hydrolase Virulence Factor from Pseudomonas aeruginosa

  摘要：

  The virulence factor cystic fibrosis transmembrane conductance regulator (CFTR) inhibitory factor (Cif) is secreted by Pseudomonas aeruginosa and is the founding member of a distinct class of epoxide hydrolases (EHs) that triggers the catalysis-dependent degradation of the CFTR. We describe here the development of a series of potent and selective Cif inhibitors by structure-based drug design. Initial screening revealed la (KB2115), a thyroid hormone analog, as a lead compound with low micromolar potency. Structural requirements for potency were systematically probed, and interactions between Cif and la were characterized by X-ray crystallography. On the basis of these data, new compounds were designed to yield additional hydrogen bonding with residues of the Cif active site. From this effort, three compounds were identified that are 10-fold more potent toward Cif than our first-generation inhibitors and have no detectable thyroid hormone-like activity. These inhibitors will be useful tools to study the pathological role of Cif and have the potential for clinical application.

  DOI：

  10.1021/acs.jmedchem.6b00173

文献信息

• Synthesis and Structure-Activity Relationships of Oxamic Acid and Acetic Acid Derivatives Related to L-Thyronine
  作者：Naokata Yokoyama、Gordon N. Walker、Alan J. Main、James L. Stanton、Michael M. Morrissey、Charles Boehm、Allan Engle、Alan D. Neubert、Jong M. Wasvary

  DOI：10.1021/jm00004a015

  日期：1995.2

  Aryloxamic acids 7 and 23, (arylamino)acetic acids 29, arylpropionic acids 33, arylthioacetic acids 37, and (aryloxy)acetic acid 41 related to L-triiodothyronine (L-T3) were prepared and tested in vitro for binding to the rat liver nuclear L-T3 receptor and the rat membrane L-T3 receptor. The structure-activity relationships for these compounds are described, with 7f, 23a, 29c, 33a, 37b, and 41 showing

  制备了与L-三碘甲甲状腺素（L-T3）有关的芳基草酸7和23，（芳基氨基）乙酸29，芳基丙酸33，芳基硫代乙酸37和（芳氧基）乙酸41并在体外测试了与大鼠肝脏的结合核L-T3受体和大鼠膜L-T3受体。描述了这些化合物的构效关系，其中7f，23a，29c，33a，37b和41对核受体显示出出色的效价（IC50分别为0.19、0.16、1.1、0.11、3.5和0.10 nM）。并显着降低了对膜受体的结合亲和力（IC50> 5 microM）。这些化合物中的某些，尤其是草酰胺酸系列7和23，对甲基取代的衍生物（例如7f和23a）表现出空前的效价。化合物7f和23a在具有ED50'的大鼠中显示出良好的降脂作用
• Heteroacetic acid derivatives
  申请人：Ciba-Geigy Corporation

  公开号：US05401772A1

  公开（公告）日：1995-03-28

  Disclosed are compounds of formula ##STR1## wherein R is hydroxy, esterified hydroxy or etherified hydroxy; R.sub.1 is halogen, trifluoromethyl or lower alkyl; R.sub.2 is halogen, trifluoromethyl or lower alkyl; R.sub.3 is halogen, trifluoromethyl, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl or cycloalkyl-lower alkyl; or R.sub.3 is the radical ##STR2## wherein R.sub.8 is hydrogen, lower alkyl, aryl, cycloalkyl, aryl-lower alkyl or cycloalkyl-lower alkyl; R.sub.9 is hydroxy or acyloxy; R.sub.10 represents hydrogen or lower alkyl; or R.sub.9 and R.sub.10 together represent oxo; R.sub.4 is hydrogen, halogen, trifluoromethyl or lower alkyl; X is --NR.sub.7, S or O; W is O or S; R.sub.5 represents hydrogen, lower alkyl or aryl-lower alkyl;and R.sub.6 represents hydrogen; or R.sub.5 and R.sub.6 together represent oxo provided that X represents --NR.sub.7; R.sub.7 represents hydrogen or lower alkyl; Z represents carboxyl, carboxyl derivatized as a pharmaceutically acceptable ester or as a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; which are useful as hypocholesteremic agents.

  揭示了以下式的化合物##STR1##其中R是羟基，酯化羟基或醚化羟基；R.sub.1是卤素，三氟甲基或较低烷基；R.sub.2是卤素，三氟甲基或较低烷基；R.sub.3是卤素，三氟甲基，较低烷基，芳基，芳基-较低烷基，环烷基或环烷基-较低烷基；或R.sub.3是基团##STR2##其中R.sub.8是氢，较低烷基，芳基，环烷基，芳基-较低烷基或环烷基-较低烷基；R.sub.9是羟基或酰氧基；R.sub.10代表氢或较低烷基；或R.sub.9和R.sub.10一起代表氧代；R.sub.4是氢，卤素，三氟甲基或较低烷基；X是--NR.sub.7，S或O；W是O或S；R.sub.5代表氢，较低烷基或芳基-较低烷基；和R.sub.6代表氢；或R.sub.5和R.sub.6一起代表氧代，前提是X代表--NR.sub.7；R.sub.7代表氢或较低烷基；Z代表羧基，羧基衍生物，作为药学上可接受的酯或作为药学上可接受的酰胺；及其药学上可接受的盐；这些化合物可用作降胆固醇药物。
• Indole carboxylic acids as thyroid receptor ligands
  申请人：——

  公开号：US20030078289A1

  公开（公告）日：2003-04-24

  A compound of the formula 1 wherein W, R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , R 7 , R 8 and R 13 are as defined herein, useful in the treatment of obesity, overweight condition, hyperlipidemia, glaucoma, cardiac arrhythmias, skin disorders, thyroid disease, hypothyroidism, thyroid cancer and related disorders and diseases such as diabetes mellitus, atherosclerosis, hypertension, coronary heart disease, congestive heart failure, hypercholesteremia, depression, osteoporosis and hair loss.

  一种化合物的公式1，其中W，R1，R2，R3，R4，R5，R6，R7，R8和R13如本文所定义，在治疗肥胖、超重症、高脂血症、青光眼、心律失常、皮肤疾病、甲状腺疾病、甲状腺功能减退症、甲状腺癌及相关疾病和疾病（如糖尿病、动脉粥样硬化、高血压、冠心病、充血性心力衰竭、高胆固醇血症、抑郁症、骨质疏松症和脱发）的治疗中有用。
• 一种作为甲状腺激素β受体激动剂的化合物及其用途
  申请人：凯思凯旭（上海）医药科技有限公司

  公开号：CN113979963A

  公开（公告）日：2022-01-28

  本发明涉及一种作为甲状腺激素β受体激动剂的化合物及其用途，进一步涉及式(1)所示的化合物或其药学上可接受的形式、包含其的药物组合物、及其制备方法。本发明所述的化合物或药物组合物可以用于制备预防、治疗或减轻由甲状腺激素β受体调节的疾病的药物。
• Oxamic acid derivatives as hypocholesteremic agents
  申请人：CIBA-GEIGY AG

  公开号：EP0580550A1

  公开（公告）日：1994-01-26

  Disclosed are compounds of formula wherein    R is hydrogen, hydroxy, esterified hydroxy or etherified hydroxy;    R₁ is hydrogen, halogen, trifluoromethyl or lower alkyl;    R₂ is hydrogen, halogen, trifluoromethyl or lower alkyl;    R₃ is halogen, trifluoromethyl, lower alkyl, aryl, aryl-lower alkyl, cycloalkyl or cycloalkyl-lower alkyl; or    R₃ is the radical wherein R₈ is hydrogen, lower alkyl, aryl, cycloalkyl, aryl-lower alkyl or cycloalkyl-lower alkyl; R₉ is hydroxy or acyloxy; R₁₀ represents hydrogen or lower alkyl; or R₉ and R₁₀ together represent oxo;    R₄ is hydrogen, halogen, trifluoromethyl or lower alkyl;    X is -NR₇;    W is O or S;    R₅ and R₆ together represent oxo;    R₇ represents hydrogen or lower alkyl;    Z represents carboxyl, carboxyl derivatized as a pharmaceutically acceptable ester or as a pharmaceutically acceptable amide; and pharmaceutically acceptable salts thereof; which are useful as hypocholesteremic agents.

  所公开的是式 其中 R 是氢、羟基、酯化羟基或醚化羟基； R₁ 是氢、卤素、三氟甲基或低级烷基； R₂ 是氢、卤素、三氟甲基或低级烷基； R₃ 是卤素、三氟甲基、低级烷基、芳基、芳基-低级烷基、环烷基或环烷基-低级烷基；或 R₃ 是基团 其中 R₈ 是氢、低级烷基、芳基、环烷基、芳基-低级烷基或环烷基-低级烷基；R₉ 是羟基或酰氧基；R₁₀ 代表氢或低级烷基；或 R₉ 和 R₁₀ 共同代表氧代； R₄ 是氢、卤素、三氟甲基或低级烷基； X 是-NR₇； W 是 O 或 S； R₅ 和 R₆ 共同代表氧代； R₇ 代表氢或低级烷基； Z 代表羧基、作为药学上可接受的酯或作为药学上可接受的酰胺的羧基衍生物；及其药学上可接受的盐；可用作降胆固醇药。